Alzheimer's: The risks of monoclonal antibodies may outweigh benefits

Researchers are reporting that the risks from monoclonal antibody treatments for Alzheimer's appear to outweigh the benefits, so these therapies probably people shouldn't be used on most people with the disease

Related Keywords

United States ,American ,Mark Ebell ,Hernandez Sorokina Stocksy ,Mike Gorenchtein ,University Of Georgia ,American Academy Of Family Physicians ,Northwell Health ,American Cancer Society ,Drug Administration ,American Academy ,Medical News ,